PEGS_Banner_Biologics-Autoimmune


The specificity, efficacy and safety profiles of biologics make them good candidates for the treatment of the complex array of autoimmune diseases, but challenges remain related to clinical endpoints, isolation of responder populations and how to best develop and apply treatment combinations. Emerging genetic understandings of the mechanisms of these complex disorders are now being combined with exciting new therapeutic formats and strategies in a renewed wave of attention for the use of biotherapeutics in this therapeutic area. Biologics for Autoimmune Diseases presents a focused meeting that will offer an exciting exploration of ways in which the industry is applying new science and technology in the development of a next generation of effective and safe therapeutics.

KEYNOTE PRESENTATION: The Impact of the Accelerated Medicines Program on the Development of Biologics for Autoimmune Diseases

Michael B. Brenner, M.D., Theodore B. Bayles Professor of Medicine, Harvard Medical School; Chief, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital

FEATURED PRESENTATION: Unmet Medical Needs in Autoimmune Diseases: Opportunities for Biotherapeutics

Roland Kolbeck, Ph.D., Senior Director, Research, Respiratory, Inflammation & Autoimmunity, MedImmune


EMERGING TARGETS

CSF1 and IL34 Cytokines as Therapeutic Targets in Macrophage-Driven Inflammation

Ali Zarrin, Ph.D., Scientist, Immunology, Genentech

Pharmacokinetic and Pharmacodynamic Relationship of AMG 811, an Anti-IFN-γ IgG1 Monoclonal Antibody, in Patients with Systemic Lupus Erythematosus

Ping Chen, Ph.D., Scientist, Quantitative Pharmacology, Amgen, Inc.

Activated Invariant NKT Cells Control Central Nervous System Autoimmunity in a Mechanism that Involves Myeloid-Derived Suppressor Cells

Vrajesh Parekh, Ph.D., Research Assistant Professor, Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine

Modulation of TLRs for Potential Treatment of Rare Autoimmune Diseases

Louis Brenner, M.D., Senior Vice President and CMO, Idera Pharmaceuticals, Inc.

The Complement System as a Potential Target for Biologics against Autoimmune Diseases

V. Michael Holers, M.D., Head, Division of Rheumatology, University of Colorado, Denver

Dampening Pathological Immune Responses via Targeting OX40 with GBR 830, an Antagonist Monoclonal Antibody

Jonathan Back, Ph.D., Head, In Vivo Pharmacology, Biologics Research, Glenmark Pharmaceuticals, Switzerland

Selective Modulation of Fc Receptors for Improved Therapy of Orphan Autoimmune Diseases: Lessons from IVIg

Tony Manning, Ph.D., Vice President, Research, Momenta Pharmaceuticals


INFLAMMATORY CYTOKINES

Clinical Update for Secukinumab, an Anti-IL-17 Antibody for Treatment of Psoriasis

Franco Di Padova, Ph.D., Director, Novartis Institutes for Biomedical Research, Switzerland

Generation of Novel Bispecific Antibodies against TNFα and IL-17 with Different Binding Properties

Stefan Seeber, Ph.D., Principal Scientist, Large Molecule Research, Roche Pharma Research & Early Development, Roche Innovation Center Penzberg, Germany

The Emerging Landscape of RORγt Biology

Daniel Cua, Ph.D., Senior Principal Scientist, Autoimmunity and Inflammation Merck Research Laboratories


BIOMARKERS AND CLINICAL ENDPOINTS

Predictive Biomarker Discovery in Proof-of-Concept Clinical Studies in Inflammatory Diseases: 3 Case Studies

Joseph R. Arron, M.D., Ph.D., Associate Director & Senior Scientist, Biomarker Discovery, Genentech

Endpoints and Clinical Trial Design for Biologics in Autoimmune Diseases

Matthew Linnik, Ph.D., Senior Research Fellow, Autoimmunity, Eli Lilly and Company


NEW BIOLOGICS PLATFORMS FOR AUTOIMMUNE INDICATIONS

Clinical Update for COVA322, a Bispecific Antibody Inhibiting TNF and IL-17A for Rheumatoid and Psoriatic Arthritis

Mathias Locher, Ph.D., Chief Development Officer, Covagen AG, Switzerland

ARGX-113, A Novel Fc-Based Therapeutic Approach for Antibody-Induced Pathologies

Peter Ulrichts, Ph.D., Scientist, arGEN-X BV, Belgium



For more details on the conference, please contact:
Kent Simmons
Program Director
Cambridge Healthtech Institute
Phone: 207-869-9199
E-mail: ksimmons@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471
E: dinerstein@healthtech.com